

# **Exhibit 1**

**SUPERIOR COURT FOR THE DISTRICT OF COLUMBIA**  
**Civil Division**

**THERESA M. OWENS**  
**147 Beechnut Road**  
**Westwood, MA 02090**

**Plaintiff,**


**v.**

**ELI LILLY AND COMPANY**  
**Lilly Corporate Center, Indianapolis, IN 46285**  
**w/s/o NATIONAL REGISTERED AGENTS, INC.**  
**1090 Vermont Avenue, NW, #910**  
**Washington, DC 20005**

**Defendant.**

**CIVIL ACTION NO.**

0006884-02



**COMPLAINT**

**(DES Litigation – Products Liability, Punitive Damages)**

1. Jurisdiction is founded upon 11 D.C. Code §921 (1981 ed.).
2. Defendant is engaged, or has been engaged, in the manufacturing, marketing, sale, promotion, and distribution of pharmaceuticals throughout the United States, and is doing business in the District of Columbia. The Defendant met with and conspired with numerous pharmaceutical manufacturers in the District of Columbia, prior to obtaining governmental approval for DES. Defendant spearheaded industry-wide conferences in the District of Columbia to seek approval of DES by Joint Submission, withholding from the Food and Drug Administration reports questioning the efficacy of DES and studies raising serious questions of safety. These meetings, conferences and agreements occurred in the District of Columbia.

**COUNT I**

**(Negligence)**

3. On or about 1962, during her pregnancy with Theresa M. Owens, the mother of the Plaintiff herein bought and ingested DES in Massachusetts. Her physician prescribed said

drug during the pregnancy. The drug was manufactured and sold by Defendant Eli Lilly and Company.

4. As a result of Plaintiff's embryonic exposure to DES, she suffered injuries, including, but not limited to, uterine and cervical malformations, with resulting infertility, and incurred medical expenses for care and treatment, and suffered physical and mental pain and suffering.

5. Said injuries were the result of the negligence of Defendant, including, but not limited to, failure to test, failure to warn, over-promotion of DES, and failure to heed and report adverse studies regarding the safety and efficacy of DES.

**COUNT II**  
**(Strict Liability)**

6. All of the allegations contained in Count I are realleged and incorporated herein by reference.

7. DES is, and at all times relevant to this action was, an unreasonably dangerous and defective drug when used by pregnant women for its advertised and intended purpose as a preventative of miscarriage.

8. Defendant is engaged, or has been engaged, in the business of producing DES, and is, or has been, a commercial manufacturer of said drug.

9. Plaintiff's mother purchased and ingested DES during her pregnancy with Plaintiff, and received and ingested DES in the same form and condition as when it left Defendant's possession.

10. Said product was defective when placed on the market by Defendant. DES was sold by Defendant without sufficient warning or instructions. A reasonable seller would not

have sold the product had he/she known of the risks involved. The risks were greater than a reasonable buyer would expect.

11. Defendant knew, or should have known, that pregnant women and their attending physicians could not realize and could not detect the dangerous and harmful nature of DES. Clear warnings as to the doubtful efficacy of DES and dangers to unborn children should have been disseminated to overcome Defendant's extensive advertising campaigns proclaiming the safety and efficacy of DES.

12. As a result of Defendant's marketing and promotion of said defective and unreasonably dangerous drug, Plaintiff was exposed to DES as an unborn child and has suffered injury, loss, and damages as aforesaid.

13. By reason of having marketed and promoted DES in its defective and unreasonably dangerous condition, Defendant is strictly liable to Plaintiff for her DES-related injuries, losses, and damages.

**COUNT III**  
**(Breach of Warranty)**

14. All of the allegations contained in Counts I and II are realleged and incorporated herein by reference.

15. At all times relevant to this action, Defendant marketed and promoted DES accompanied by implied and express warranties and representations to physicians and their patients that the drug was efficacious as a miscarriage preventative, and was safe for pregnant women and their unborn children if used as directed for such purposes.

16. Defendant knew, or should have known, that pregnant women, including the mother of Plaintiff and her attending physicians, were relying on Defendant's skills and judgments, and the implied and express warranties and representations.

17. At all times relevant to this action, these implied and express warranties and representations were false, misleading, and unfounded. In fact, DES was a misbranded drug in violation of federal law, and was neither safe nor efficacious as a miscarriage preventative.

18. As a direct result of the breach of warranties by the Defendant, Plaintiff has been injured as aforesaid.

**COUNT IV**  
**(Misrepresentation)**

19. All of the allegations contained in Counts I, II, and III are realleged and incorporated herein by reference.

20. Defendant represented to pregnant women, including the mother of Plaintiff and her attending physicians, in promotion campaigns, advertisements, labeling, and literature that DES was safe, effective, and adequately tested, which representations were made and publicized with the purpose and intent of having physicians and their patients rely on them.




21. The mother of the Plaintiff and her attending physicians did, in fact, rely on Defendant's representations in his advice about purchase, use, and consumption of DES.

22. At all times relevant to this action, these representations were known to Defendant to be false or they were made by Defendant in conscious, reckless and/or unreasonable disregard of facts available to Defendant, indicating a lack of efficacy and a danger to pregnant women and their unborn children.

23. As a direct result of said false representations by Defendant, Plaintiff was injured as aforesaid.

**WHEREFORE**, Plaintiff Theresa M. Owens, demands judgment against Defendant in the sum of Two Million Dollars (\$2,000,000.00), as compensatory damages, plus costs.


Respectfully submitted,  
AARON M. LEVINE & ASSOCIATES

  
\_\_\_\_\_  
Aaron M. Levine, #7864  
1320 19<sup>th</sup> Street, N.W., Suite 500  
Washington, D.C. 20036  
(202) 833-8040  
\_\_\_\_\_  
Brandon J. Levine, #412130  
\_\_\_\_\_  
Renee L. Robinson-Meyer, #455575  
\_\_\_\_\_  
Steven J. Lewis, #472564

Counsel for Plaintiff

#### DEMAND FOR JURY TRIAL

Plaintiff hereby demands a trial by jury as to all issues of material facts.

  
\_\_\_\_\_  
Aaron M. Levine